Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05815485 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Salim S. Hayek to The University of Texas Medical Branch, Galveston
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 2 to 3
    v4
  2. Secondary endpoints: 8 to 7
    • Eligibility criteria expanded, about 1 word
    • Study title expanded, about 2 words
    v3
  3. Start date changed from estimate of Apr 2023 to May 4, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Trial Details
NCT Number NCT05815485
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions
(from sponsor)		 COVID-19
Related terms Acute Kidney Injury, COVID-19
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov